Showing results (71-80 of 243) with videos related to
Sort By:
Pageof 25
Respiratory Medicine|March 30, 2025
Pulse corticosteroid therapy in interstitial lung disease-associated with anti-aminoacyl-tRNA synthetase antibodies: Comparable efficacy with potential for reduced adverse eventsShota Kaburaki, Toru Tanaka, Koichiro Kamio, et al.Oncotargets and Therapy|March 24, 2025
Clinical Impact of Osimertinib Dose Reduction in the First-Line Setting on EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Monocentric StudyHirokazu Iso, Makiko Yomota, Yukari Shirakura, et al.Anticancer Research|January 30, 2022
A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and PemetrexedNatsuki Takano, Masahiro Seike, Teppei Sugano, et al.Cancer Medicine|September 11, 2023
Osimertinib early dose reduction as a risk to brain metastasis control in EGFR-mutant non-small cell lung cancerTakehiro Tozuka, Rintaro Noro, Akihiko Miyanaga, et al.Journal of Cancer Research and Clinical Oncology|July 13, 2023
Influence of background cardiovascular risk factors on VEGF inhibitor-related adverse vascular events in patients with non-small cell lung cancer: a retrospective studyTomoyuki Naito, Yuji Minegishi, Hideaki Shiraishi, et al.Cureus|December 7, 2021
Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary DiseaseMizuki Yuasa, Yosuke Tanaka, Tohru Tanaka, et al.Human Vaccines & Immunotherapeutics|May 18, 2022
Kikuchi-Fujimoto disease can present as delayed lymphadenopathy after COVID-19 vaccinationTakeru Kashiwada, Yoshinobu Saito, Yasuhiro Terasaki, et al.Oncology Reports|September 19, 2014
MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesotheliomaKazuo Yamamoto, Masahiro Seike, Susumu Takeuchi, et al.Respiratory Medicine Case Reports|June 12, 2023
Successful immunosuppressant-free treatment of a drug-induced sarcoidosis-like reaction caused by dupilumabSho Saito, Masamitsu Shimizu, Ryota Miyashita, et al.Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi|March 29, 2019
Organizing Pneumonia after Nivolumab Treatment in a Patient with Pathologically Proven Idiopathic Pulmonary FibrosisTakeru Kashiwada, Yuji Minegishi, Yoshinobu Saito, et al.Pageof 25